Eli Lilly says late-stage trial of pancreatic cancer treatment failed to meet its main goal of overall survival [MarketWatch]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: MarketWatch
Eli Lilly says late-stage trial of pancreatic cancer treatment failed to meet its main goal of overall survival Eli Lilly and Co. LLY, +1.67% said Wednesday a late-stage trail of a treatment for pancreatic cancer did not meet its main goal of overall survival. The company said detailed results of the phase 3 trial called Sequoia evaluating pegilodecakin plus FOLFOX (folinic acid, 5-FU, oxaliplatin) compared to FOLFOX alone in patients with metastatic pancreatic cancer will be presented at a future medical meeting. Metastatic pancreatic cancer is one of the deadliest major cancers with just 3% of patients that are diagnosed in the U.S. surviving five years after being diagnosed. The disease is the third leading cause of cancer deaths and is expected to become the second leading cause in the next 10 years. "While we are disappointed by the outcome of the SEQUOIA study, we look forward to the upcoming results in lung cancer, learning from those results and increasing our understanding
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Corticosteroids Market Size Expected to Reach USD 6.91 Bn by 2033 [Yahoo! Finance]Yahoo! Finance
- As Zepbound shortage grows, Eli Lilly says there's no immediate end in sight [MSNBC.com]MSNBC.com
- The Zacks Analyst Blog Highlights Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo [Yahoo! Finance]Yahoo! Finance
- Weight loss drug Zepbound may help people with obstructive sleep apnea, drugmaker says [CNN]CNN
- Top Research Reports for Eli Lilly, Linde & Caterpillar [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/6/24 - Miss
LLY
Sec Filings
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- LLY's page on the SEC website